PT1771468E - Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart) - Google Patents

Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart) Download PDF

Info

Publication number
PT1771468E
PT1771468E PT05764208T PT05764208T PT1771468E PT 1771468 E PT1771468 E PT 1771468E PT 05764208 T PT05764208 T PT 05764208T PT 05764208 T PT05764208 T PT 05764208T PT 1771468 E PT1771468 E PT 1771468E
Authority
PT
Portugal
Prior art keywords
cells
tumor necrosis
liart
genetic engineering
induce apoptosis
Prior art date
Application number
PT05764208T
Other languages
English (en)
Portuguese (pt)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of PT1771468E publication Critical patent/PT1771468E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT05764208T 2004-07-29 2005-07-21 Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart) PT1771468E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Publications (1)

Publication Number Publication Date
PT1771468E true PT1771468E (pt) 2010-04-20

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05764208T PT1771468E (pt) 2004-07-29 2005-07-21 Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart)

Country Status (24)

Country Link
US (1) US20070264231A1 (https=)
EP (2) EP1621550A1 (https=)
JP (1) JP5042826B2 (https=)
KR (1) KR20070047757A (https=)
CN (1) CN101076540B (https=)
AT (1) ATE455847T1 (https=)
AU (1) AU2005266543B2 (https=)
BR (1) BRPI0513855A (https=)
CA (1) CA2571426A1 (https=)
DE (1) DE602005019050D1 (https=)
DK (1) DK1771468T3 (https=)
ES (1) ES2340400T3 (https=)
HR (1) HRP20100227T1 (https=)
IL (1) IL180233A (https=)
MX (1) MX2007001152A (https=)
NO (1) NO20070956L (https=)
NZ (1) NZ552223A (https=)
PL (1) PL1771468T3 (https=)
PT (1) PT1771468E (https=)
RS (1) RS51381B (https=)
RU (1) RU2390558C2 (https=)
SI (1) SI1771468T1 (https=)
WO (1) WO2006010558A1 (https=)
ZA (1) ZA200701231B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199423A1 (en) * 2004-06-18 2008-08-21 Genentech, Inc. Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
AU2015335607B2 (en) 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP6974681B2 (ja) * 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US6852703B1 (en) * 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
PL1771468T3 (pl) 2010-07-30
HRP20100227T1 (hr) 2010-07-31
CN101076540A (zh) 2007-11-21
MX2007001152A (es) 2007-04-18
RS51381B (sr) 2011-02-28
WO2006010558A8 (en) 2006-08-24
ATE455847T1 (de) 2010-02-15
IL180233A0 (en) 2007-07-04
IL180233A (en) 2010-12-30
NZ552223A (en) 2009-01-31
AU2005266543B2 (en) 2012-02-02
SI1771468T1 (sl) 2010-07-30
WO2006010558A1 (en) 2006-02-02
EP1771468B1 (en) 2010-01-20
ZA200701231B (en) 2008-08-27
CA2571426A1 (en) 2006-02-02
CN101076540B (zh) 2012-10-24
EP1621550A1 (en) 2006-02-01
NO20070956L (no) 2007-02-20
JP2008507961A (ja) 2008-03-21
DK1771468T3 (da) 2010-05-25
KR20070047757A (ko) 2007-05-07
EP1771468A1 (en) 2007-04-11
DE602005019050D1 (de) 2010-03-11
RU2390558C2 (ru) 2010-05-27
RU2007107369A (ru) 2008-09-10
HK1110874A1 (en) 2008-07-25
US20070264231A1 (en) 2007-11-15
BRPI0513855A (pt) 2008-05-20
JP5042826B2 (ja) 2012-10-03
ES2340400T3 (es) 2010-06-02
AU2005266543A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
PT1771468E (pt) Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart)
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
ATE526987T1 (de) Dr5-antikörper und deren verwendung
MX2020009512A (es) Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
IL188101A0 (en) Use of hif 1-alpha modulators for treatment of cancer
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
HK1245287A1 (zh) IL13RAα2结合剂和其在癌症治疗中的用途
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MX2024000678A (es) Agentes que codifican elementos de union a cldn6 y cd3 para el tratamiento de canceres positivos para cldn6.
PE20081841A1 (es) Composiciones farmaceuticas con capacidad de induccion de apotosis en celulas tumorales, utiles para el diagnostico y tratamiento de la leucemia linfocitica cronica b
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
ATE555215T1 (de) Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
PT1427420E (pt) Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro
MX2022006278A (es) Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.
MX2025008839A (es) Anticuerpos
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
DE602005023138D1 (de) Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
Kaufmann Cure in metastatic disease
TW200640948A (en) DR5 antibodies and uses thereof
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.